Vyriad officials say that the company's G-Link platform can address some of the most persistent challenges in in vivo delivery.

In part 1 of our interview with Leland Metheny, MD, he explained how a new triple-target chimeric antigen receptor (CAR) T-cell therapy works in multiple myeloma. In part 1 of our interview with ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma. A next-generation "armored" CAR T cell therapy ...

Over the last decade, the cellular cancer immunotherapy known as CAR T-cell therapy has roared to the rescue of many blood cancer patients. The engineered immune cells revolutionized treatment of ...

Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of refractory or relapsed leukemia and hematologic malignancies, particularly over the past decade. Despite its ...

Chimeric antigen receptor-T (CAR-T) cell therapy represents a major breakthrough in cancer immunotherapy, providing remarkable clinical benefits for ...

While the use of radiation bridging therapy (BT) in chimeric antigen receptor (CAR) T-cell therapy for blood cancer is expanding, plenty of unanswered questions remain on topics such as ideal timing ...

In vivo CAR T-cell therapy could revolutionize cancer treatment by bypassing traditional manufacturing, reducing costs, and minimizing adverse events. Kelonia Therapeutics' KLN-1010 has shown ...

Doctors at the University of Washington and Fred Hutch Cancer Center have better characterized an emerging complication of chimeric antigen receptor (CAR) T-cell therapy. A recent paper in Movement ...